Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001628280-26-029376
- form_type
- 8-K
- ticker
- MANE
- cik
- 0001827635
- company_name
- Veradermics, Inc
- filed_at
- 2026-05-01T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:33.032065+00:00
- generated_at
- 2026-05-15T00:21:49.504275+00:00
- sec_items
- ["1.01", "3.02", "9.01"]
- event_type
- other_material
- sentiment
- positive
- materiality_score
- 0.9
- calibrated_materiality_score
- 0.9
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001628280-26-029376
- json_url
- https://secwatch.observer/filing/0001628280-26-029376.json
- markdown_url
- https://secwatch.observer/filing/0001628280-26-029376.md
- text_url
- https://secwatch.observer/filing/0001628280-26-029376.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1827635/000162828026029376/0001628280-26-029376-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1827635/000162828026029376/mane-20260501.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
CLRB
Cellectar raises ~$35M via stock/warrant offering; reports positive 12-mo Phase 2b WM data
Cellectar Biosciences, Inc.
May 8, 2026, 7:59 PM ET
other_material
Items 1.01, 3.02, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 3.02, 9.01
same event type: other_material
similar materiality
This filing
On May 1, 2026, the Company closed a private placement (“the Private Placement”) pursuant to a Securities Purchase Agreement (the “Purchase Agreement”), dated April 29, 2026, among the Company and certain entities affiliated with Suvretta Capital (each, an “Investor” and collectively, the “Investors”), in which the Company sold to the Investors pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 300,000 shares of Common Stock, at an offering price of $99.99999 per Pre-Funded Warrant. The gross proceeds of the Private Placement were approximately $30.0 million
Comparable filing
pursuant to an additional securities purchase agreement with certain members of the executive management team of the Company (the “Management Purchase Agreement”
Filing page
SEC filing
SUJA
Suja Life completes IPO of 8.9M shares at $21/share; closes May 8, 2026
SUJA LIFE, INC.
May 8, 2026, 7:59 PM ET
other_material
Items 1.01, 3.02, 3.03, 5.03, 5.02, 9.01
same fact type: material_agreement
same SEC item: 1.01, 3.02, 9.01
same event type: other_material
similar materiality
This filing
On May 1, 2026, the Company closed a private placement (“the Private Placement”) pursuant to a Securities Purchase Agreement (the “Purchase Agreement”), dated April 29, 2026, among the Company and certain entities affiliated with Suvretta Capital (each, an “Investor” and collectively, the “Investors”), in which the Company sold to the Investors pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 300,000 shares of Common Stock, at an offering price of $99.99999 per Pre-Funded Warrant. The gross proceeds of the Private Placement were approximately $30.0 million
Comparable filing
On May 6, 2026, Suja Life, Inc. (the “Company”) and Suja Life Holdings, L.P. (“Holdings LP”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, Jefferies LLC, and William Blair & Company, L.L.C., as representatives of the several underwriters named therein (collectively, the “Underwriters”) relating to the initial public offering (the “IPO”) of the Company’s Class A common stock
Filing page
SEC filing
AREB
American Rebel exchanges $1.77M preferred & note for ~5.97M common shares to Streeterville
AMERICAN REBEL HOLDINGS INC
May 8, 2026, 7:59 PM ET
other_material
Items 1.01, 3.02, 9.01
same fact type: material_agreement
same SEC item: 1.01, 3.02, 9.01
same event type: other_material
similar materiality
This filing
On May 1, 2026, the Company closed a private placement (“the Private Placement”) pursuant to a Securities Purchase Agreement (the “Purchase Agreement”), dated April 29, 2026, among the Company and certain entities affiliated with Suvretta Capital (each, an “Investor” and collectively, the “Investors”), in which the Company sold to the Investors pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 300,000 shares of Common Stock, at an offering price of $99.99999 per Pre-Funded Warrant. The gross proceeds of the Private Placement were approximately $30.0 million
Comparable filing
Streeterville
Series E Preferred Exchange Agreements On
April 30, 2026, the Company entered into three Exchange Agreements (the “Exchanges”) with Streeterville.
Filing page
SEC filing
AVTX
Avalo Therapeutics raises ~$405M in public offering; preliminary cash $82M as of March 31
Avalo Therapeutics, Inc.
May 7, 2026, 7:59 PM ET
other_material
Items 1.01, 2.02, 7.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: other_material
similar materiality
This filing
On May 1, 2026, the Company closed a private placement (“the Private Placement”) pursuant to a Securities Purchase Agreement (the “Purchase Agreement”), dated April 29, 2026, among the Company and certain entities affiliated with Suvretta Capital (each, an “Investor” and collectively, the “Investors”), in which the Company sold to the Investors pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 300,000 shares of Common Stock, at an offering price of $99.99999 per Pre-Funded Warrant. The gross proceeds of the Private Placement were approximately $30.0 million
Comparable filing
On May 5, 2026, Avalo Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives of the underwriters listed in Schedule A thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of (a) 19,730,000 shares (the “Shares”) of its common stock, par value $0.001 per share (“Common Stock”), at a price to the public of $17.75 per Share, and (b) pre-funded warrants to purchase up to 1,400,000 shares of Common Stock (the “Pre-Funded Warrants”), at a price to the public of $17.749 per Pre-Funded Warrant, which represents the per share public offering price for the Shares less the $0.001 per share exercise price for each such Pre-Funded Warrant (the “Offering”).
Filing page
SEC filing
GPCR
Structure Therapeutics Amends Sales Agreement to Raise ATM Capacity to $400M and Reports Q1 2026 Financials
Structure Therapeutics Inc.
May 7, 2026, 7:59 PM ET
other_material
Items 1.01, 2.02, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: other_material
similar materiality
This filing
On May 1, 2026, the Company closed a private placement (“the Private Placement”) pursuant to a Securities Purchase Agreement (the “Purchase Agreement”), dated April 29, 2026, among the Company and certain entities affiliated with Suvretta Capital (each, an “Investor” and collectively, the “Investors”), in which the Company sold to the Investors pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 300,000 shares of Common Stock, at an offering price of $99.99999 per Pre-Funded Warrant. The gross proceeds of the Private Placement were approximately $30.0 million
Comparable filing
On May 7, 2026, Structure Therapeutics Inc. (the “Company”) amended and restated that certain Sales Agreement dated August 6, 2025 (the “Sales Agreement” and as amended and restated, the “Amended and Restated Sales Agreement”) with Leerink Partners LLC and Cantor Fitzgerald & Co. (collectively, the “Sales Agents”), relating to the offer and sale of the Company’s American Depositary Shares (“ADSs”), each representing three ordinary shares, $0.0001 par value per ordinary share.
Filing page
SEC filing
HWH
HWH enters $10M PIPE with warrants at $0.50/share; terminates Hapi Metaverse acquisition
HWH International Inc.
May 7, 2026, 7:59 PM ET
other_material
Items 1.01, 1.02, 5.02, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: other_material
similar materiality
This filing
On May 1, 2026, the Company closed a private placement (“the Private Placement”) pursuant to a Securities Purchase Agreement (the “Purchase Agreement”), dated April 29, 2026, among the Company and certain entities affiliated with Suvretta Capital (each, an “Investor” and collectively, the “Investors”), in which the Company sold to the Investors pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 300,000 shares of Common Stock, at an offering price of $99.99999 per Pre-Funded Warrant. The gross proceeds of the Private Placement were approximately $30.0 million
Comparable filing
On May 5, 2026, HWH International Inc., a Nevada corporation (the “Company”) entered into a term sheet (the “Term Sheet”) with Smart Dynamics Technology Limited, a company incorporated in the British Virgin Islands (the “Investor”), pursuant to which the Company has agreed to sell to the Investor, for an aggregate purchase price of $10,000,000
Filing page
SEC filing
DGAC
Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE
DISCIPLINED GROWTH ACQUISITION Corp
June 1, 2026, 4:15 PM ET
other_material
Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 3.02, 9.01
same event type: other_material
This filing
On May 1, 2026, the Company closed a private placement (“the Private Placement”) pursuant to a Securities Purchase Agreement (the “Purchase Agreement”), dated April 29, 2026, among the Company and certain entities affiliated with Suvretta Capital (each, an “Investor” and collectively, the “Investors”), in which the Company sold to the Investors pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 300,000 shares of Common Stock, at an offering price of $99.99999 per Pre-Funded Warrant. The gross proceeds of the Private Placement were approximately $30.0 million
Comparable filing
A Share Rights Agreement, dated May 26, 2026, by and between the Company and Odyssey Transfer and Trust Company, as rights agent
Filing page
SEC filing
CITR
CitroTech exchanges all Series A Preferred for Series C Convertible; BoltRock gets board rights
CitroTech Inc.
June 1, 2026, 4:15 PM ET
other_material
Items 1.01, 3.02, 9.01
same fact type: material_agreement
same SEC item: 1.01, 3.02, 9.01
same event type: other_material
This filing
On May 1, 2026, the Company closed a private placement (“the Private Placement”) pursuant to a Securities Purchase Agreement (the “Purchase Agreement”), dated April 29, 2026, among the Company and certain entities affiliated with Suvretta Capital (each, an “Investor” and collectively, the “Investors”), in which the Company sold to the Investors pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 300,000 shares of Common Stock, at an offering price of $99.99999 per Pre-Funded Warrant. The gross proceeds of the Private Placement were approximately $30.0 million
Comparable filing
On May 28, 2026, CitroTech Inc., a Wyoming corporation (the “Company”), entered into Stock Exchange and Stockholders Agreements (the “Exchange Agreements”) with the holders (the “Holders”) of the Company’s outstanding Series A Preferred Stock
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.